Healthcare
Cogent Biosciences, Inc.(COGT)
Live Price
Offline$33.10
+1.47% today
1Y Change
+406.93%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $6.00B
- Revenue Growth
- 0.0%
- EPS Growth
- -3.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cogent Biosciences, Inc. (COGT) is a Healthcare stock with a market cap of $6.00B and listed on NASDAQ. The stock last traded around $33.10 and up 406.9% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -3.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -3.7%, free cash flow -27.7% with operating margin 0.0% and ROIC -42.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines COGT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -3.7%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +41.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -3.0% | -6.6% | -12.8% |
2026 Feb 17, 2026 | -7.8% | +1.9% | +4.1% | -5.8% |
2025 Nov 7, 2025 | +7.4% | +119.0% | +126.3% | +171.9% |
Benchmark Edge
COGT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COGT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COGT Max Drawdown
-26.34%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COGT and SPY.
Company Overview
Cogent Biosciences, Inc.
NASDAQ
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing small-molecule precision therapies for genetically defined diseases. It focuses on modulating the tumor microenvironment, particularly through inhibitors targeting colony-stimulating factor 1 receptor (CSF1R), a regulator of tumor-associated macrophages that promote tumor growth and immune evasion. The company's lead candidate, an orally bioavailable CSF1R inhibitor, is in early-stage clinical trials for solid tumors, demonstrating preclinical antitumor activity alone and combined with checkpoint inhibitors. Cogent Biosciences also advances CGT9486, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V mutations and other KIT exon 17 alterations, addressing systemic mastocytosis, gastrointestinal stromal tumors, and additional solid tumor indications. Its pipeline emphasizes immune-regulatory pathways in oncology, leveraging collaborations with academic institutions and contract research organizations. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences plays a vital role in advancing targeted immuno-oncology treatments to address unmet needs in precision medicine.
- Leadership
- Mr. Andrew R. Robbins M.B.A.
- Employees
- 258
- Street Address
- 275 Wyman Street, 3rd Floor
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.1
Growth
- Revenue
- 0.0%
- EPS
- -3.7%
- Free Cash Flow
- -27.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -83.3%
- ROIC
- -42.8%
Balance Sheet
- Debt/Equity
- 0.39
- Current Ratio
- 15.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.